Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Bradley Paul Morgan is active.

Publication


Featured researches published by Bradley Paul Morgan.


Tetrahedron Letters | 1998

Solid phase synthesis of phosphinopeptoids as transition state analog inhibitors

Peter Hans Dorff; Gordon Chiu; Steven Wayne Goldstein; Bradley Paul Morgan

Abstract A procedure for preparing novel phosphinopeptoids, 1 , on a solid support is described. The key step in the synthesis includes a conjugate addition of the trivalent form of a protected aminomethylphosphinic acid ( 5 ) to a resin-bound acrylate.


Synthetic Communications | 2003

New, Scalable Route for the Synthesis of a trans-Fused Hexahydro-1H-phenanthren-2-one from a Conjugated Tetrahydro-3H-phenanthren-2-one

Bradley Paul Morgan; Richard V. Trilles; Graeme F. Woodworth

Abstract A three-step, readily scalable route for the conversion of a ring-conjugated tetrahydro-3H-phenanthren-2-one to a trans-fused hexahydro-1H-phenanthren-2-one is described. The key step is the hydrogenation of a double bond using a nearby ketal moiety to assist in the stereoselective delivery of the hydrogen.


Drugs of The Future | 2008

Glucocorticoid receptor modulators

Robert L. Dow; Kevin K.-C. Liu; Bradley Paul Morgan; Andrew G. Swick


Journal of Medicinal Chemistry | 2002

Discovery of Potent, Nonsteroidal, and Highly Selective Glucocorticoid Receptor Antagonists

Bradley Paul Morgan; Andrew G. Swick; Diane M. Hargrove; Janet A. LaFlamme; Melinda S. Moynihan; Richard S. Carroll; Kelly A. Martin; Eunsun Lee; and Debra Decosta; Jon Bordner


Journal of Medicinal Chemistry | 2009

Octahydrophenanthrene-2,7-diol analogues as dissociated glucocorticoid receptor agonists: discovery and lead exploration.

Ralph P. Robinson; Leonard Buckbinder; Amber I. Haugeto; Patricia A. McNiff; Michele L. Millham; Matthew R. Reese; Jean Schaefer; Yuriy A. Abramov; Jon Bordner; Yves A. Chantigny; Edward F. Kleinman; Ellen R. Laird; Bradley Paul Morgan; John C. Murray; Eben Salter; Matthew D. Wessel; Sue A. Yocum


Archive | 2003

beta3 adrenergic receptor agonists

Jennifer Lafontaine; Bradley Paul Morgan


Journal of Medicinal Chemistry | 2003

In vitro and in vivo characterization of 3-{2-[6-(2-tert-butoxyethoxy)pyridin-3-yl]-1H-imidazol-4-yl}benzonitrile hydrochloride salt, a potent and selective NPY5 receptor antagonist

Richard L. Elliott; Robert M. Oliver; Marlys Hammond; Terrell A. Patterson; Li She; Diane M. Hargrove; Kelly A. Martin; Tristan S. Maurer; J. Cory Kalvass; Bradley Paul Morgan; Paul DaSilva-Jardine; Ralph W. Stevenson; Christine M. Mack; James V. Cassella


Archive | 2000

Thyromimetic antiobesity agents

Peter Cornelius; Diane M. Hargrove; Bradley Paul Morgan; Andrew G. Swick


Letters in Drug Design & Discovery | 2004

Discovery of Potent, Non-Steroidal and Highly Selective Glucocorticoid Receptor Antagonists with Anti-Obesity Activity

Bradley Paul Morgan; Kevin K.-C. Liu; Deepak K. Dalvie; Andrew G. Swick; Diane M. Hargrove; Theresa C. Wilson; Janet A. LaFlamme; Melinda S. Moynihan; Margaret A. Rushing; Graeme F. Woodworth


Archive | 2000

Compositions containing apo B secretion/MTP inhibitors and anti-obesity agents and use thereof

Bradley Paul Morgan; Andrew G. Swick

Collaboration


Dive into the Bradley Paul Morgan's collaboration.

Researchain Logo
Decentralizing Knowledge